Savara (SVRA) Jumped, But What Is Behind The Fresh Attention?

Savara’s CHEST 2026 data and what it means for investors

Savara (SVRA) is back on investors’ radars after presenting new poster data from its IMPALA trial at the CHEST 2026 meeting in Phoenix, centered on molgramostim in a small subgroup of aPAP patients.

The fresh analysis focused on people whose lung diffusion capacity looked relatively preserved on paper, with DLco% above 70%, yet still showed clear signs of impaired gas transfer and burden of surfactant in the lungs.

Savara’s latest CHEST 2026 update lands against a mixed tape, with the share price up 7.11% on the day to $4.52 yet down 19.86% year to date, while total shareholder return over five years is very large at about 3.7x. This signals that long term holders have already seen substantial gains even as recent momentum has faded and short term price moves react sharply to clinical data headlines.

Spot patterns in how clinical-stage stories trade by lining up Savara next to 21 high quality undiscovered gems that are still off most investors’ radar.

After a 7.11% one-day jump yet a near 60% gap to analyst targets, Savara now sits between a bargain narrative and a caution flag. Is the discount compensation for trial risk or a misread of aPAP optionality?

Price-to-Book of 8x: Is it justified for Savara?

On the latest numbers, Savara trades on a P/B ratio of 8x, which prices the stock well above book value and well above many peers.

P/B compares the equity value on the balance sheet to what the market is willing to pay for that equity. For an early stage biotech like Savara with $0 in revenue and a net loss of $139.3m, that multiple is really a shorthand for how investors view the value of molgramostim and the broader rare respiratory pipeline rather than current financial performance.

The gap between the 8x P/B and the US Biotechs industry average of 1.8x is wide. Against a peer group average of 4.2x, it still looks expensive, which suggests the share price already embeds a meaningful degree of optimism on future revenue forecasts, profitability timelines and aPAP adoption.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-book of 8x (OVERVALUED)

Still, the molgramostim story leans heavily on a single Phase 3 program, and any trial setback or financing squeeze at a US$1.07b valuation could quickly puncture today’s premium.

Find out about the key risks to this Savara narrative.

Next Steps

If the mix of optimism and concern around Savara feels finely balanced, move quickly, review the trial and valuation data yourself, and then consider the 1 key reward and 2 important warning signs

Looking for more investment ideas beyond Savara?

If Savara has sharpened your focus on risk and reward, do not stop here. Use data backed screeners to pressure test your next move.

• Target potential mispricings by scanning a curated 29 high quality undervalued stocks that may offer stronger risk adjusted entry points than a single biotech story.
• Prioritise resilience by filtering for a list of solid balance sheet and fundamentals (24 results) so fragile funding profiles do not quietly erode your thesis.
• Hunt for fresh opportunities among a 21 high quality undiscovered gems that larger investors may not be watching yet but still show solid fundamentals.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com